Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

RL cells:1.5 ± 0.1 nM (0.22 mg/ml), Ramos cells:1 ± 0.1 nM (0.15 mg/ml)

METHODS: B cells were treated with 0, 2.5, 5 and 10 μg/mL Rituximab to observe the effect of Rituximab on B cell proliferation.
RESULTS There was an optimal inhibition of B cell proliferation at a concentration of 5 μg/mL. [1]

METHODS: 100 mg of Rituximab was administered over 4 h. Rituximab was then infused in a regimen of 3 weekly infusions for 4 weeks, and caspase-3 and PARP expression and protein hydrolysis processes were examined in patients.
RESULTS Rituximab induced cleavage of caspase-3, followed by the appearance of a 17-kd cleavage product corresponding to the large subunit of the catalytically active protease, and cleavage of PARP, a known substrate of cysteine asparaginase, was also detected. [2]

Objective: Complement-mediated cell lysis. Concentrations: 0, 0.02, 0.2, 2, 20 μg/mL. Incubation Time: 2 h. Method: Lymphoma B cells were purified from lymph node biopsies of patients with B-cell lymphoma. Rituximab was added to tumor cells (1×106 /mL) in complete medium supplemented by human serum, inactivated or not by incubation at 56°C for 30 minutes. After 2 hours at 37°C, cell lysis was determined by PI staining of cells and analysis by flow cytometry.